Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain MetastasesSarah A Weiss, Dijana Djureinovic, Wei Wei, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 TherapySarah A Weiss, Mario Sznol, Montaser Shaheen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1Sarah A Weiss, Dijana Djureinovic, Shlomit Jessel, et al.Nature Immunology|July 27, 2021
Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humansKathleen B Yates, Pierre Tonnerre, Genevieve E Martin, et al.Molecular Cancer|November 15, 2023
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterDijana Djureinovic, Sarah A Weiss, Irina Krykbaeva, et al.Nature|July 21, 2017
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy targetRobert T Manguso, Hans W Pope, Margaret D Zimmer, et al.Biorxiv : the Preprint Server for Biology|February 12, 2026
Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 ImmunotherapyMatthew P Zimmerman, Amy C Huang, Emily K Cox, et al.Journal for Immunotherapy of Cancer|October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.Nature Immunology|October 5, 2019
Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockadeBrian C Miller, Debattama R Sen, Rose Al Abosy, et al.Nature Immunology|September 17, 2024
Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral controlSarah A Weiss, Amy Y Huang, Megan E Fung, et al.Pageof 6